Cardiac Regeneration Technologies,
LLC (CRT) is a clinical stage company and subsidiary
of TRT that is committed to neovascularization and
increasing collateral pathways within the myocardium. The use of SoftWave™
therapy directly on the surface of the heart shows preliminary results
of increased blood flow, increase in the ejection fraction and
a marked improvement in cardiac performanc
e.Image: Under the guidance of Prof. Michael Grimm, the first patient was successfully treated with DESWT during a CABG procedure on September 23, 2008.
CRT has completed initial animal
trials using our Softwave™
technology to treat cardiovascular disease in rat and pig hearts.
Our human heart clinical trial commenced in Vienna in September 2008
under the direction of Prof. Michael Grimm of the University of
Vienna. The study has
demonstrated the safety of the technology and has
shown very promising results
which are under review for publication.
To learn more about the trial click here.
For more information about CRT, please
contact us at info@trtllc.com